What Is GLP-1 Therapy and How Does It Work?

GLP-1 medications have moved from a niche diabetes treatment to one of the most discussed topics in medicine in the span of a few years — and the conversation isn’t slowing down. Semaglutide, tirzepatide, and their relatives have produced weight loss results in clinical trials that were previously thought to require surgical intervention. For men dealing with excess weight that hasn’t responded to diet and exercise — particularly the kind that drives metabolic dysfunction and hormonal disruption — understanding what these drugs actually do and how they work matters more than the headlines.

This article covers the mechanism, the evidence, who these medications are appropriate for, and how they fit into a broader approach to metabolic and hormonal health.

What Is a GLP-1 Receptor Agonist?

GLP-1 stands for glucagon-like peptide-1 — a hormone produced naturally in the gut, primarily by L-cells in the small intestine and colon. It is released in response to food intake and plays a central role in regulating blood sugar, appetite, gastric emptying, and insulin secretion.

GLP-1 receptor agonists (GLP-1 RAs) are synthetic compounds designed to mimic or enhance the action of this natural hormone. They bind to GLP-1 receptors throughout the body — in the pancreas, stomach, brain, heart, and other tissues — and activate the same signaling pathways that endogenous GLP-1 triggers, but with a longer duration of action. Natural GLP-1 has a half-life of 1–2 minutes; therapeutic GLP-1 RAs are engineered to last hours to weeks depending on the formulation.

The key compounds in current clinical use include:

• Semaglutide — FDA-approved as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). Weekly subcutaneous injection or daily oral tablet (Rybelsus).
• Tirzepatide — FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management). Weekly injection. Acts on both GLP-1 and GIP receptors — a dual agonist with larger effect sizes than single GLP-1 agonists in trials.
• Liraglutide — older generation, daily injection. Approved as Victoza (diabetes) and Saxenda (weight management). Less potent than semaglutide or tirzepatide for weight loss.

These are peptide medications — short chains of amino acids — which is why they’re often discussed alongside other peptide therapies in the context of men’s health optimization. For a broader overview of how peptides work as a drug class, the guide to peptides for men over 35 provides useful context.

How GLP-1 Therapy Works: The Mechanism

GLP-1 receptor agonists work through multiple simultaneous pathways. Understanding all of them helps explain why the weight loss effects are more robust than most prior pharmacological approaches.

Appetite suppression via the brain

GLP-1 receptors are densely distributed in the hypothalamus and brainstem — brain regions that regulate hunger, satiety, and food reward. When GLP-1 RAs activate these receptors, they reduce appetite signals and increase satiety signals. Most patients describe this as a reduction in food “noise” — the persistent preoccupation with food that many overweight individuals experience. Cravings, particularly for high-calorie foods, tend to diminish meaningfully. This central mechanism is what separates GLP-1 RAs from most prior appetite suppressants, which worked primarily through stimulant or monoamine pathways.

Slowed gastric emptying

GLP-1 receptors in the stomach slow the rate at which food moves from the stomach into the small intestine. This delays nutrient absorption and prolongs the sensation of fullness after eating. Meals feel more satisfying at smaller volumes, and the time between hunger signals extends significantly for most patients.

Insulin and glucagon regulation

In the pancreas, GLP-1 RAs stimulate insulin secretion in a glucose-dependent manner — meaning they increase insulin release when blood sugar is elevated, but not when it’s normal. This is why they carry very low hypoglycemia risk when used without other diabetes medications. They simultaneously suppress glucagon (which raises blood sugar), improving overall glucose regulation. This mechanism made them valuable as diabetes treatments before their weight loss potential became apparent.

Cardiovascular and metabolic effects

GLP-1 receptors are present in cardiac tissue, blood vessels, and the kidneys. Beyond weight loss, clinical trials have demonstrated direct cardiovascular benefits from GLP-1 RAs independent of glycemic control — including reduced risk of major adverse cardiovascular events in high-risk patients. The SELECT trial (2023) showed that semaglutide reduced cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease, adding a new indication and generating significant clinical attention.

What the Evidence Shows: Weight Loss Results

The clinical trial data for GLP-1 RAs — particularly semaglutide and tirzepatide — is unusually strong for a pharmacological intervention.

The STEP 1 trial (2021) randomized 1,961 adults with obesity (no diabetes) to weekly semaglutide 2.4 mg or placebo over 68 weeks. The semaglutide group lost an average of 14.9% of body weight compared to 2.4% in the placebo group. Approximately one-third of participants achieved weight loss of 20% or more — a threshold previously associated only with bariatric surgery.

The SURMOUNT-1 trial (2022) evaluated tirzepatide in a similar population. At the highest dose (15 mg weekly), participants lost an average of 20.9% of body weight over 72 weeks. More than half achieved at least 20% weight loss. These results exceeded semaglutide in head-to-head comparisons and established tirzepatide as the current most effective pharmacological weight loss option available.

For men specifically, visceral fat reduction is among the most clinically significant outcomes. Visceral fat — the fat that accumulates around the organs in the abdominal cavity — drives insulin resistance, cardiovascular risk, and hormonal disruption. It is also the type of fat most strongly associated with low testosterone in men. The relationship between excess weight, hormonal imbalance, and how they reinforce each other is explored in the article on whether low testosterone causes weight gain.

GLP-1 Therapy and Testosterone: The Connection

The relationship between obesity, GLP-1 therapy, and testosterone is clinically significant and frequently underappreciated. Excess visceral fat is one of the primary drivers of low testosterone in adult men — through two main mechanisms.

First, adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol. Higher body fat means more aromatase activity, which means more testosterone being converted to estrogen. This lowers the testosterone-to-estrogen ratio and suppresses the hypothalamic-pituitary-gonadal axis, reducing testicular testosterone production further.

Second, obesity is associated with insulin resistance and elevated inflammatory markers, both of which independently suppress HPG axis function and testosterone production.

Studies on men who lose significant weight — whether through lifestyle, surgery, or pharmacological intervention — consistently show improvements in testosterone levels. A 2024 analysis examining semaglutide’s effects in men with obesity found meaningful increases in total and free testosterone following significant weight loss, alongside reductions in estradiol. The implication: for some men with secondary hypogonadism driven primarily by obesity, GLP-1 therapy that achieves significant weight loss may improve testosterone without direct hormone replacement.

This doesn’t mean GLP-1 therapy replaces TRT in men with confirmed hypogonadism — it means that in men who are significantly overweight with borderline-low testosterone, addressing the weight component is an important first step before concluding that testosterone replacement is necessary. The testosterone therapy evaluation overview covers how this factor is incorporated into clinical decision-making.

Who Is a Candidate for GLP-1 Therapy?

Current FDA-approved indications for GLP-1 RAs in the weight management context are:

• BMI ≥ 30 (obesity), or
• BMI ≥ 27 (overweight) with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease

These are the approved criteria for weight management indications (Wegovy, Zepbound). The diabetes indications (Ozempic, Mounjaro) have different prescribing criteria based on HbA1c and glucose management goals.

Table 1 — GLP-1 therapy candidate profiles. Prescribing decisions require full clinical evaluation by a licensed physician. Insurance coverage varies significantly by indication and plan.

Semaglutide vs. Tirzepatide: Key Differences

Both medications are weekly injectables in the same drug class, but they differ in mechanism and effect size in ways that matter clinically.

Table 2 — Semaglutide vs tirzepatide comparison as of 2026. Pricing reflects U.S. list prices without insurance or manufacturer savings programs; actual out-of-pocket cost varies significantly. See the weight loss overview for current program information.

Side Effects and What to Expect

GLP-1 RAs have a well-characterized side effect profile, with gastrointestinal effects being the most common reason for dose adjustment or discontinuation.

The muscle mass concern is particularly relevant for men over 40, in whom lean mass preservation is already a priority. Research consistently shows that combining GLP-1 therapy with resistance training significantly reduces the proportion of weight lost as lean tissue versus fat. For men already experiencing reduced muscle mass or strength — which may have a hormonal component — the connection to testosterone and growth hormone is worth exploring. The overview of 7 signs of low growth hormone covers how GH deficiency presents alongside metabolic dysfunction.

GLP-1 Therapy and the Bigger Picture: Metabolic Health in Men

GLP-1 therapy doesn’t exist in isolation. For men with significant excess weight, particularly visceral fat accumulation, the hormonal and metabolic effects of obesity are interconnected in ways that a single intervention may not fully address.

Excess body fat suppresses testosterone, raises estradiol, increases insulin resistance, worsens sleep quality (and therefore growth hormone production), and raises inflammatory markers that blunt cellular response to androgens. Addressing the weight component with an effective pharmacological intervention creates a more favorable hormonal environment — but the underlying hormonal deficiencies may still require direct evaluation.

The relationship between low testosterone, weight, and the bidirectional effects they have on each other is covered in the complete TRT guide. For men with both significant weight excess and confirmed low testosterone, a comprehensive evaluation that addresses both conditions is often more effective than treating either in isolation.

If fatigue, reduced libido, and poor body composition are part of the picture alongside significant weight, the overview of symptoms that aren’t always recognized as hormonal provides a useful framework for identifying what may need to be evaluated beyond weight.

Frequently Asked Questions

Is GLP-1 therapy the same as “Ozempic”?

Ozempic is a brand name for semaglutide approved for type 2 diabetes management. “GLP-1 therapy” refers to the broader drug class that includes semaglutide, tirzepatide, liraglutide, and others. Wegovy is the same molecule as Ozempic (semaglutide) but at a higher dose specifically approved for chronic weight management. They are not interchangeable prescriptions despite sharing an active ingredient, as the approved indications, dosing regimens, and insurance coverage differ.

Will I regain weight when I stop GLP-1 therapy?

Clinical data consistently shows that weight regain occurs when GLP-1 RAs are discontinued. The STEP 4 trial demonstrated that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of lost weight over the following 48 weeks, while those who continued maintained their loss. This reflects the chronic nature of obesity as a condition — it requires ongoing management, similar to how hypertension requires ongoing antihypertensive treatment. GLP-1 therapy is most effective as part of a long-term metabolic management strategy rather than a short-term course.

Do GLP-1 medications require a prescription?

Yes — all approved GLP-1 receptor agonists are prescription medications in the United States. They require a physician evaluation, documented clinical indication, and ongoing medical supervision. Compounded versions of semaglutide became widely available during periods of drug shortage but carry different regulatory and quality considerations than FDA-approved branded products. A licensed physician should guide formulation choice.

Can GLP-1 therapy help with fatty liver disease (NAFLD)?

Emerging evidence suggests yes. Visceral fat reduction and improved insulin sensitivity from GLP-1 therapy have been shown to reduce hepatic steatosis (fatty liver) in multiple studies. The NASH indication is under active investigation. For men with confirmed NAFLD alongside obesity and metabolic syndrome, this represents an additional potential benefit beyond weight loss alone.

How long does it take to see results with semaglutide or tirzepatide?

Most patients notice appetite reduction within the first 1–2 weeks at low doses. Meaningful weight loss (5–10%) typically occurs within the first 12–16 weeks. Maximum weight loss is generally achieved around 60–72 weeks at therapeutic doses. The dose escalation schedule — which is designed to minimize GI side effects — means the first 12–20 weeks are primarily titration rather than full therapeutic dosing.

Does GLP-1 therapy affect testosterone levels?

Indirectly, yes — through weight loss. Significant reductions in visceral fat reduce aromatase activity (which converts testosterone to estrogen) and improve HPG axis function. Studies in obese men show testosterone increases following significant weight loss achieved through any means, including GLP-1 therapy. Direct GLP-1 receptor effects on testosterone production are still being investigated. Men with significantly low testosterone should be evaluated separately, as weight loss alone may not fully restore levels in confirmed hypogonadism.

What’s the difference between GLP-1 therapy and a diet program?

Diet programs work through conscious caloric restriction and behavioral modification — they require sustained effort against biological hunger signals. GLP-1 receptor agonists change the underlying biology: they reduce the hunger signals themselves, slow gastric emptying, and alter the brain’s food reward response. This is why the clinical trial results for GLP-1 RAs exceed what’s achievable with behavioral interventions alone in most populations. They are complementary — GLP-1 therapy is most effective when combined with dietary guidance and physical activity.

Is GLP-1 therapy safe long-term?

GLP-1 RAs have been used in clinical practice for over 15 years (liraglutide was first approved in 2010). Long-term cardiovascular outcomes trials have shown safety and benefit in high-risk populations. The black-box warning regarding thyroid C-cell tumors is based on animal data at doses far exceeding clinical use; human epidemiological data has not confirmed elevated thyroid cancer risk. The full long-term safety profile of the newer higher-dose formulations (semaglutide 2.4 mg, tirzepatide 15 mg) will continue to accumulate as post-marketing surveillance matures.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
4. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022;327(2):138–150. doi:10.1001/jama.2021.23619
5. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. doi:10.1016/j.cmet.2006.01.004
6. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 2023;58:101882. doi:10.1016/j.eclinm.2023.101882
7. U.S. Food & Drug Administration. FDA approves new drug treatment for chronic weight management. fda.gov — Wegovy approval